Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health technology tags : Cancer save search
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ANIX | $3.12 0.65% 0.64% 33K
|
Health Technology
|
| O: -1.89%
H: 0.0%
C: 0.0%
business cancer
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
| Email alert
Add to watchlist
onct-534 first cancer treatment for study
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
tacti-004 lung positive cancer cell for trial
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 26.26%
H: 73.2%
C: 18.87%
health cancer care for commercial
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
CVAC | $2.44 0.0% 790K
|
Health Technology
|
| O: -0.38%
H: 3.41%
C: 0.95%
cancer collaboration
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
URGN | $13.78 -3.37% -3.48% 390K
|
Health Technology
|
| O: 1.46%
H: 1.17%
C: -1.44%
ugn-103 fda drug bladder cancer for application
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 4.76%
H: 0.45%
C: -5.91%
drug candidate liver cancer treat namodenoson advanced
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
AGEN | $5.3 6.64% 6.23% 1.5M
|
Health Technology
|
| O: 1842.45%
H: 0.0%
C: 0.0%
cancer
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
Published: 2024-04-11 (Crawled : 21:00) - biospace.com/
MEIP | $3.3 1.54% 1.52% 26K
|
Health Technology
|
| O: 0.27%
H: 1.71%
C: -3.71%
me-344 avastin pharma cancer study
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: 0.0%
biotech fda breast cancer for meeting trial submission
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 8.28%
H: 0.56%
C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: -2.97%
H: 0.0%
C: 0.0%
com503 cancer research immunology potential
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
MNPR | $0.636 -6.19% -6.6% 33K
|
Health Technology
|
| O: 4.98%
H: 4.84%
C: 3.23%
mnpr-101 cancer for trial advanced
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
PRPH | $5.15 -5.33% -5.63% 99K
|
Health Technology
|
| O: -7.22%
H: 2.98%
C: 1.49%
management test cancer
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -2.03%
H: 2.35%
C: -2.76%
association direct cancer research meeting
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
STTK | $9.58 -5.43% -5.74% 420K
|
Health Technology
|
| O: -1.11%
H: 9.78%
C: 9.66%
association presentation cancer research preclinical for meeting
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
RAPT | $7.96 0.38% 0.38% 790K
|
Health Technology
|
| O: 0.0%
H: 3.37%
C: 1.44%
cancer immunotherapy trial therapeutics results
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: -3.82%
H: 0.0%
C: -13.49%
mdna113 association cancer research preclinical for meeting
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.